Patient Profile
MVP members 18–75 years of age with Diabetes (Type 1 and Type 2) and who have had a nephropathy screening or monitoring test, OR evidence of nephropathy documented in the medical record annually.

This includes documentation of one of the following each year:

- A nephropathy screening or monitoring test (any urine test for albumin or protein).
- Evidence of treatment for nephropathy OR ACE/ARB therapy.
- Documentation of medical attention for diabetic nephropathy, renal insufficiency, proteinuria, albuminuria, renal dysfunction, CKD, or ARF.
- A visit with a Nephrologist.
- Evidence of Stage IV CKD, ESRD, dialysis, or a kidney transplant.

Refer to the Comprehensive Diabetes Care (CDC) Overview Tip Sheet for exclusions to this sub-measure.

How to Implement Best Practices and Improve Performance

- A current medication list in the chart indicating that a patient is on an ACE/ARB agent will satisfy the requirement for medical attention to nephropathy.
- A urine dipstick (for protein) provided annually in your office will also satisfy this requirement. Be sure to submit a claim for it.
- Coordinate an exchange of information with specialists such as Nephrologists and Endocrinologists. Engage providers out of the area that may care for patients at a seasonal location.
- Consult the MVP Gaps in Care Report (GIC) for a list of delinquent CDC-Nephropathy members.
- Enable electronic medical record alerts for staff to prevent delinquent testing, reports, and visits.
- Consider the use and maintenance of a Diabetes Flowchart for efficient Nephropathy tracking.
- Exchange laboratory data with your local Regional Health Information Organization (RHIO).

Information related to all 2019 HEDIS measures has been extracted from the NCQA 2019 HEDIS Technical Specifications Volume 2.
A claim for any of the following medications will satisfy the medical attention for nephropathy requirement. For information on medications covered by MVP, see the MVP Medicaid Drug Formulary available by visiting mvphealthcare.com and selecting Providers, then Pharmacy, then MVP Formularies.

**ACE Inhibitor/ARB Medications**

Visit ncqa.org for a comprehensive list of ACE Inhibitor/ARB Medications.

<table>
<thead>
<tr>
<th>Angiotensin Converting Enzyme Inhibitors</th>
<th>Benazepril</th>
<th>Captopril</th>
<th>Enalapril</th>
<th>Fosinopril</th>
<th>Lisinopril</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moexipril</td>
<td>Perinfopril</td>
<td>Quinapril</td>
<td>Ramipril</td>
<td></td>
<td>Trandolapril</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Angiotensin II Inhibitors</th>
<th>Azilsartan</th>
<th>Candesartan</th>
<th>Eprosaran</th>
<th>Irbesartan</th>
<th>Losartan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olmesartan</td>
<td>Telmisartan</td>
<td>Valsartan</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


*Use of drugs listed here will score the sub-measure as compliant. Remember to reference the MVP Formulary to learn which of these medications are covered by the member’s plan.*

**Billing Codes**

### Medical Attention for Nephropathy

**CPT Codes**

**Urine Macroalbumin Tests**

8100–81003, 81005, 82042–82044, 84156

**CPT Category II Codes**

**Positive Urine Macroalbumin Tests**

3060F, 3062F

**Negative Urine Macroalbumin Tests**

3061F

**Evidence of Treatment for Nephropathy**

**Nephropathy Screening Tests**

81000–81003, 81005, 82042–82044, 84156

**CPT Category II Codes**

**Nephropathy Screening Test**

3060F, 3061F

**Treatment for Nephropathy**

3066F, 4010F